A phase III, open-label, mono-centre, follow-up extension study to evaluate the persistence of immune response to GSK Biologicals' HPV vaccine in healthy Chinese female subjects who received three doses of the vaccine in the HPV-058 study.
Phase of Trial: Phase III
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical intraepithelial neoplasia
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 25 Jul 2018 Status changed from recruiting to completed.
- 01 Mar 2018 Status changed from not yet recruiting to recruiting.
- 15 Feb 2018 Planned End Date changed from 16 Jul 2018 to 30 Jun 2018.